Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Expands Novartis Oncology radioligand pipeline with exclusive worldwide rights to develop and commercialize therapeutic applications for a library of FAP assets including FAPI-46 and FAPI-74.
Lead Product(s): FAPI-46 Targeted Radioligand Therapy
Therapeutic Area: Oncology Product Name: FAPI-46
Highest Development Status: Phase IProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 30, 2021